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Abstract
To assess potential differences in epidemiology and management of patients admitted with influenza infection in the intensive care unit
(ICU) during the first post-pandemic influenza period. Observational prospective study comparing September 2009–January 2010 with
September 2010–January 2011. Variables captured: demographics, co-morbidities, physiological parameters, outcomes and management.
Analysis was performed using SPSS v. 13.0; significance was set at p 0.5. Data from 53 patients, 38 adults (age, median 41.5 years; inter-
quartile range (IQR) 32.8–51.3) and 15 children (age, median 2 years, IQR 0.5–9) are presented. Vaccination rates were 0% and 4.3%
during the first and second periods, respectively. Differences postpandemic were: 100% of episodes developed after December com-
pared with 16.7% in the 2009 season. Younger children were affected (median age 0.8 years (IQR 0.3–4.8) vs 7 years (IQR 1.25–11.5),
p 0.05) and influenza B caused 8.7% of ICU admissions. Influenza A (H1N1) 2009 and respiratory syncytial virus epidemics occurred
simultaneously (42.8% of children) and bacterial co-infections doubled (from 10% to 21.7%); the prevalence of co-infections (viral or
bacterial) increased from 10% to 39.1% (OR 5.8, 95% CI 1.3–24.8). Respiratory syndromes without chest X-ray opacities reflecting
exacerbation of asthma or chronic obstructive pulmonary disease, bronchitis or bronchiolitis increased (from 6.9% to 39.1%, p <0.05)
and pneumonia decreased (from 83.3% to 56.5%, p <0.05). Primary viral pneumonia predominated among ICU admissions. Postpandemic
ICU influenza developed later, with some cases of influenza B, more frequent bacterial and viral co-infections and more patients with
severe acute respiratory infection with normal chest X-ray. Increasing vaccination rates among risk-group individuals is warranted to
prevent ICU admission and death.
Keywords: H1N1 (2009), ICU admission, influenza, primary viral pneumonia
Original Submission: 3 March 2011; Revised Submission: 30 May 2011; Accepted: 20 June 2011
Editor: R. Charrel
Article published online: 27 June 2011
Clin Microbiol Infect 2012; 18: 374–380
10.1111/j.1469-0691.2011.03617.x
Corresponding author: J. Rello, MD, PhD Critical Care
Department. Hospital Vall d’ Hebron. Ps Vall d’ Hebron 119. Anexe
5a Planta. 08035 Barcelona, Spain
E-mail: jrello@vhebron.net
Introduction
Influenza A (H1N1) 2009 infections were first identified in
Mexico in April 2009 [1]. Less than 2 months later, the
WHO declared the ‘novel influenza’ as the first pandemic of
the 21st century (http://www.who.int/mediacentre/news/
statements/2009/h1n1_pandemic_phase6_20090611/en/index.
html). Mortality rates reported in this first period were as
high as 38%, ranging from 14.3% (Australia and New Zea-
land) to 46% (Argentina) [2–4]. In Spain mortality during the
pandemic year was reported to be 25% [2]. In autumn 2010
a new wave of influenza A (H1N1) 2009 was reported, rais-
ing important concerns (http://www.who.int/csr/disease/influ-
enza/2010_12_17_GIP_surveillance/en/index.html) [5]. The
aim of this study is to present clinical experience acquired in
a single Spanish centre from patients admitted in the inten-
sive care unit (ICU) with documented influenza infection and
compare data with those of the previous year.
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Methods
This is a prospective, observational cohort study of patients
admitted in the paediatric (0–18 years old) and adult
(>18 years old) ICUs of Vall d’Hebron University Hospital of
Barcelona, Spain. The study was approved by the Institutional
Ethics Committee; because of its observational nature,
informed consent was waived. Data were recorded in an
anonymous format using the European Society of Intensive
Care Medicine (ESICM) registry. Adult data were also
reported to the National Registry developed by the Spanish
Society of Intensive Care Medicine (GTEI-SEMICYUC).
Attending physicians had the full responsibility for any diag-
nostic procedure or therapeutic decision taken for the
patients as well as for the selection of patients admitted in
the ICU.
Only confirmed cases were included in the analysis. A
confirmed case of influenza A (H1N1) 2009 was defined
as an acute respiratory illness with laboratory-confirmed
influenza A (H1N1) virus infection by use of real-time RT-
PCR [6]. As a consequence of emerging epidemiological
data, confirmed cases of influenza B were retained in the
current analysis, provided that a compatible clinical syn-
drome was present with negative RT-PCR for influenza A
(H1N1) 2009 and a positive RT-PCR assay for influenza B
(http://www.cdc.gov/flu/professionals/diagnosis/clinician_guid-
ance_ridt.htm). Two commercial multiplex RT-PCR were
used subsequently: ProFlu plus (ProFlu+, Prodesse, Inc.
Gen-Probe, Waukesha, WI, USA), which detects influenza
A virus, influenza B virus and respiratory syncytial virus
(RSV), and ProFlu influenza A subtyping (ProFlu-ST, Pro-
desse, Inc. Gen-Probe), which detects seasonal H1, sea-
sonal H3 and new H1 variant subtypes of the influenza A
virus.
Clinical and epidemiological criteria were used according
to WHO definitions [7,8]. The definitions of community-
acquired pneumonia, secondary bacterial pneumonia and hos-
pital-acquired pneumonia were based on 2007 American
Thoracic Society and Infectious Disease Society of America
guidelines [9]. Primary viral pneumonia was defined in
patients presenting during the acute phase of influenza virus
illness with acute respiratory virus illness with acute respira-
tory distress syndrome and unequivocal alveolar opacification
involving two or more lobes with negative respiratory and
blood bacterial cultures (and Gram staining). Secondary bac-
terial pneumonia was considered in patients with confirma-
tion of influenza virus infection that showed recurrence of
fever, increase in cough and production of purulent sputum
plus positive bacterial or blood cultures or positive urinary
antigen assay for Legionella sp. or Streptococcus pneumoniae.
Respiratory cultures were based on tracheal aspirates
obtained immediately after intubation. Bronchoalveolar lavage
was not routinely performed because of the high risk of gen-
erating aerosols [10].
Acute renal failure was defined as need for renal
replacement therapy [11]. Obese patients were defined as
those with body mass index over 30 kg/m2 [12]. Severity
of illness was assessed by the Acute Physiology and
Chronic Health Evaluation (APACHE) II score [13] and
organ failure by the Sequential Organ Failure Assessment
(SOFA) scoring system [14] in all adult patients within 24 h
of ICU admission. Oxygenation was assessed by the PaO2/
FiO2 ratio. Systemic corticosteroid use was considered
when dosages equivalent to 24 mg/day methylprednisolone
or 30 mg/day prednisone (adult patients) or ‡1 mg/kg
methylprednisolone (paediatric patients) were given at ICU
admission [15].
All recorded variables were analysed using the SPSS 13.0
(SPSS, Chicago, IL, USA) statistical package for Windows.
Continuous variables are presented as mean ± standard devi-
ation (SD) if normally distributed or median–interquartile
range (IQR) if not normally distributed; comparison between
September 2009–January 2010 and September 2010–January
2011 cohorts was performed using the Student’s t-test or
the Mann–Whitney U-test, respectively. Categorical data
were expressed as percentages and compared using Pear-
son’s chi-squared test. All comparisons with p <0.05 were
considered significant.
Results
Clinical data are presented for 53 patients admitted to the
adult and paediatric ICUs of Vall d’Hebron Hospital with
documented infection by influenza A (H1N1) 2009 or influ-
enza B virus, during two comparative periods: 1 September
2009 to 31 January 2010 (30 patients) and 1 September
2010 to 31 January 2011 (23 patients) (Table 1).
The identification of influenza B
All 30 cases recorded during September 2009–January 2010
were confirmed cases of influenza A (H1N1) 2009 infection.
Two among 23 cases of the 2010–2011 period, were caused
by influenza B virus (8.7%). Both had risk factors; the first
was a neurologically impaired child mechanically ventilated at
home and the second was a 29-year-old HIV-positive patient
undergoing chemotherapy for non-Hodgkin’s lymphoma. Co-
infection by parainfluenza 3 virus in the first patient and by
S. pneumoniae in the second patient was documented.
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Distribution over time
Admissions by influenza A (H1N1) during the September
2009–January 2010 period spanned over 6 weeks, from the
last week of October 2009 to the first week of December
2009 and peaked in November 2009, whereas cases admit-
ted during the period September 2010–January 2011 spanned
over a 5-week period, from the third week of December
2010 to the third week of January 2011, clustering in the last
week of December.
Demographics and physiological characteristics
Epidemiological and clinical characteristics of the cases are
presented in Table 1. Among children, younger ages were
more affected in the September 2010–January 2011 period
(median 0.8 years (IQR 0.3–4.8) vs 7 years (IQR 1.25–
11.5) p 0.05), especially the age group below 2 years
(Fig. 1).
Primary viral pneumonia was the most prominent clinical
diagnosis on admission (Table 1). Pneumonia was significantly
less common during the period September 2010–January
2011 (56.5% vs 83.3%, p <0.05) (Table 2). On the other
hand, during this second season, respiratory syndromes with-
out radiographic evidence of opacities in the chest X-ray
were encountered more frequently (39.1% vs 6.7%, p <0.05).
This was probably driven by the more frequent presentation
of influenza A (H1N1) 2009 infection as acute exacerbation
of asthma or chronic obstructive pulmonary disease in adults
and as bronchitis/bronchiolitis in children during September
2010–January 2011 (21.7% vs 3.3%, p <0.05). Rates of acute
respiratory distress syndrome on presentation were identical
between the two surveyed periods, but in September 2010–
January 2011 percentages of patients with SOFA scores
above 5, APACHE II scores above 10 and PaO2/
FiO2 <100 mmHg were consistently higher than the previous
TABLE 1. Demographic and physiological characteristics of intensive care unit (ICU) patients admitted with influenza A
(H1N1) 2009 infections in Vall d’Hebron Hospital ICUs
Variable September 2009–January 2010 September 2010–January 2011 p
Age, years, median, IQR 37 (13.5–51.3) 29 (4.8–46) NS
Children, years, median, IQR 7 (1.25–11.5) 0.8 (0.3–4.8) 0.05
Adults, years, median, IQR 46.5 (35.5–53.5) 37 (29–46.8) 0.09
Sex, male n (%) 17 (56.7) 9 (39.1) 0.20
Adult, n (%) 22 (73) 16 (69.6) >0.20
Healthcare acquired infectiona, n (%) 2 (6.7) 2 (8.7) >0.20
Days symptom-to-hospital, median, IQR 4 (3–5.8) 4 (2–6) >0.20
Days hospital-to-diagnosis, mean ± SD 1.48 ± 1.5 0.9 ± 0.8 >0.20
Days hospital-to-ICU, mean ± SD 0.81 ± 1.4 0.41 ± 0.7 >0.20
APACHEb II score, mean ± SD 13.8 ± 11 16.8 ± 10.2 >0.20
SOFAb score, mean ± SD 4.7 ± 3.9 5.25 ± 2.7 0.16
Number of infiltratesc, mean ± SD 2.03 ± 1.7 2.17 ± 1.6 0.13
Normal chest X ray, n (%) 4 (13.3) 6 (26.1) >0.20
Respiratory syndrome without opacitiesd, n (%) 2 (6.7) 9 (39.1) <0.05
Shock on presentation, n (%) 10 (33.3) 8 (34.8) >0.20
Renal failure on presentation, n (%) 5 (26.3) 3 (13) >0.20
ARDS on presentation, n (%) 20 (66.7) 15 (65.2) >0.20
PaO2/FiO2 on presentation
e, mean ± SD, mmHg 120.8 ± 54.3 99.5 ± 52.5 0.15
PaO2/FiO2 <300 mmHg on presentation
e—ALI, n (%) 20 (100) 16 (100) >0.20
PaO2/FiO2 <200 mmHg on presentation
e—ARDS, n (%) 18 (90) 15 (93.8) >0.20
PaO2/FiO2 <100 mmHg on presentation
e, n (%) 7 (35) 11 (68.8) <0.05
MODS on presentation, n (%) 15 (50) 13 (56.5) >0.20
Primary viral pneumonia, n (%) 19 (65.5) 15 (65.2) >0.20
Bacterial and/or viral co-infections, n (%) 3 (10) 9 (39.1) <0.05
Bacterial co-infections, n (%) 3 (10) 5 (21.7) >0.20
Viral co-infections 1 (12.5)f 3 (42.8)f >0.20
Presence of co-morbidities, n (%) 23 (76.7) 19 (82.6) >0.20
Intubation, n (%) 16 (59.3) 12 (52.2) >0.20
Days of mechanical ventilation, median, IQR 10 (9–16) 7 (3–23) >0.20
Macrolide in combination, n (%) 10 (41.7) 15 (68.2) 0.07
Corticosteroid use, n (%) 12 (66.7) 11 (47.8) >0.20
Corticosteroids for pneumonia, n (%) 4 (13.3) 0 (0) 0.07
Gapg antiviral, days, median, IQR 2 (0–5) 2.5 (1–5) >0.20
ICU mortality, n (%) 5 (17.9) 3 (14.3) >0.20
Hospital LOS, days, median, IQR 14.5 (8.5–28.5) 11 (5.5–19) >0.20
ICU LOS, days, median, IQR 9.5 (3.3–18.8) 5.5 (3–7.8) 0.08
IQR, interquartile range; NS, non-significant; APACHE II, Acute Physiology and Chronic Health Evaluation II score; SOFA, Sequential Organ Failure Assessment score; ARDS,
acute respiratory distress syndrome; ALI, acute lung injury; MODS, multiple organ dysfunction syndrome; ICU, intensive care unit; LOS, length of stay.
aHospital transmission in patients already hospitalized for another reason.
bAPACHE II and SOFA scores refer to the adult population.
cNumber of infiltrates: number of chest X-ray quadrants with presence of infiltrates.
dRefers to exacerbation of chronic obstructive pulmonary disease or asthma or bronchitis or bronchiolitis.
eRefers to all adult patients.
fDenominator is the number of paediatric cases.
gGap antiviral: days from admission to administration of oseltamivir.
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period, denoting a more severely ill study population
(Tables 1 and 2).
Bacterial co-infections doubled (21.7% vs 10%, p >0.20)
and the total rate of co-infections (either viral or bacterial)
increased almost four-fold (39.1% vs 10%, OR 5.8, 95% CI
1.3–24.8, p 0.01) during September 2010–January 2011.
Streptococcus pneumoniae predominated among bacterial
pathogens. Among five cases of S. pneumoniae co-infection,
four were diagnosed by a positive urine antigen test and one
by positive culture of tracheal aspirates, revealing a cefotax-
ime and macrolide susceptible pneumococcus. Three more
patients had bacterial co-infection; one cancer patient had
bacteraemia with Klebsiella pneumoniae resistant only to
ampicillin; one immunocompromised patient with known co-
lonization developed pneumonia by Pseudomonas aeruginosa;
finally another diabetic patient had co-infection by Serratia
marcescens resistant to ampicillin, amoxicillin/clavulanic acid
and cefuroxime documented by positive culture of tracheal
aspirates. RSV was a prominent feature among viral co-infec-
tions during September 2010–January 2011 season (42.8% vs
12.5% of paediatric cases, p >0.20) (Table 2).
Outcomes. Outcomes were similar between cases admitted
during September 2009–January 2010 and September 2010–
January 2011 in terms of ICU mortality, length of hospital
stay and days of mechanical ventilation (Table 1). The same
applies in the subset of mechanically ventilated patients
where ICU mortality was similar in the September 2010–Jan-
uary 2011 period (25%, vs 31.3% p >0.20). No paediatric
death occurred during September 2010–January 2011. A
trend towards shorter ICU stay was demonstrated during
the second surveyed period (days, median (IQR) 5.5 (3–7.8)
vs 9.5 (3.3–18.8) p 0.08).
FIG. 1 Distribution of intensive care unit admissions across age
groups.
TABLE 2. Presenting features of
influenza A (H1N1) 2009 in
patients admitted to the Vall
d’Hebron Hospital (Barcelona)
intensive care units
Presenting feature
Number of patients (%)
p
Odds Ratioa
(95% Confidence Interval)2009–2010 2010–2011
Clinical
Pneumonia 25 (83.3) 13 (56.5) <0.05 1.95 (1.1–3.4)
Respiratory syndromes
without chest X-ray opacitiesb
2 (6.7) 9 (39.1) <0.05 –
Encephalitis 3 (10) 3 (13) >0.20 –
Cardiac failure 0 (0) 1 (4.3) >0.20 –
Severity parameters
SOFAc >5, n (%) 2 (9.1) 7 (43.8) <0.05 7.8 (1.3–45.1)
APACHEc II >10, n (%) 8 (36.4) 12 (75) <0.05 5.3 (1.3–21.9)
PaO2/FiO2 <100 mmHg
c, n (%) 7 (35) 11 (68.8) <0.05 4.1 (1–16.6)
Number of patients with co-infections
(viral or bacterial)
3 (10) 9 (39.1) <0.05 5.8 (1.3–24.8)
Virald, n (%) 1e (12.5) 4e (57.1) 0.06 –
RSV n (%) 1 (12.5) 3 (42.8) >0.20 –
Other viruses (n) – 2f – –
Bacterial, n (%) 3e (10) 5e (21.7) >0.20 –
Streptococcus pneumoniae, n (%) 3 (10) 2 (8.6) >0.20 –
Other bacteria (n) 0 3g – –
SOFA, Sequential Organ Failure Assessment score; APACHE II, Acute Physiology and Chronic Health Evaluation II
score; RSV, respiratory syncytial virus.
aOdds Ratio and 95% Confidence Interval are reported when clinically significant.
bIncludes patients admitted for acute exacerbation of chronic obstructive pulmonary disease or asthma (adults), epi-
sode of bronchitis or bronchiolitis (children).
cSOFA and APACHE II scores refer to the adult population.
dThe denominator is number of children.
eOne mixed bacterial and viral co-infection in each period.
fOne rhinovirus in an adult patient and one parainfluenza 3 virus in a child.
gPseudomonas aeruginosa (n = 1), Klebsiella pneumoniae (n = 1), Serratia spp. (n = 1).
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Risk factors. All risk factors and their distribution over the
two surveyed time periods are presented in Table 3. Obesity
was the predominant risk factor with increasing frequency
(from 13.3% in September 2009–January 2010 to 21.7% in
September 2010–January 2011). Pregnant women repre-
sented 41.7% of ICU-admitted women of reproductive age
and had no other risk factor.
Treatment. Treatment with oseltamivir was recorded in
93.8% of and 95.7% of the September 2009–January 2010
and September 2010–January 2011 periods, respectively.
Pregnant women had a significant delay from the onset of
symptoms to the onset of oseltamivir (median 6 days, range
5–10). In the period September 2010–January 2011 we
observed a significant predilection towards standard dose of
oseltamivir (100% vs 50%, OR 6.33, 95% CI 2.2–17.9). A
trend towards no administration of corticosteroids as
adjunctive treatment for pneumonia was also recorded in
the September 2010–January 2011 period (0% vs 13.3%,
p 0.07; Table 1). Corticosteroids were administered in 43.4%
of patients, mostly methylprednisolone for underlying respi-
ratory disease or hydrocortisone for shock, proportionately
distributed between the studied periods. Antibiotic coverage
was characterized by a trend towards increased administra-
tion of azithromycin as combination treatment with a third-
generation cephalosporin in the September 2010–January
2011 period (68.2% vs 46.7% p 0.07).
Ventilation parameters. Forty-five patients (84.9%) in both
periods received some type of respiratory support including
high-flow oxygen therapy, non-invasive and conventional
mechanical ventilation; 28 patients (56%) required intubation
and ventilation with no statistical difference between the
periods September 2009–January 2010 and September 2010–
January 2011. Among five ICU-admitted pregnant women,
three required intubation, all with a favourable outcome.
Vaccination status. No patient of the period September 2009–
January 2010 (0%) was vaccinated against influenza A H1N1
(2009) virus and only one patient of the period September
2010–January 2011 (4.3%) was vaccinated.
Discussion
This is the first study to report a single centre’s experience
from the 2010–2011 wave of influenza A (H1N1) 2009 ICU
infections. This report originates from one of the largest
medical centres in Spain and paediatric data were also
included in the analysis.
Younger patients were more affected in the period Sep-
tember 2010–January 2011; this was most prominent in the
paediatric population, where severe presentation of influenza
A (H1N1) 2009 infection has shifted to the age group tradi-
tionally more vulnerable to acute respiratory viral infections
[16]. Although not statistically significant, the shift to younger
ages was also observed in the adult population. This adult
population does not stem from a ‘healthy’ pool, as indicated
by the 82.6% prevalence of co-morbidities in the September
2010–January 2010 period and the majority of severity
TABLE 3. Comparative presentation of co-morbidities and risk factors among patients admitted with influenza A (H1N1)
2009 in the intensive care units of Vall d’Hebron hospital during September 2009–January 2010 and September 2010–January
2011
Co-morbidity
September 2009–January 2010
Number of patients (%)
September 2010–January 2011
Number of patients (%) p Total number of patients (%)
Obesity 4 (13.3) 5 (21.7) >0.20 9 (17)
BMI >40 2 (6.7) 2 (8.7) >0.20 4 (7.5)
BMI >30 2 (6.7) 3 (13) >0.20 5 (9.4)
Asthma 5 (16.7) 3 (13) >0.20 8 (15.1)
Diabetes 2 (6.7) 4 (17.4) 0.08 6 (11.3)
Pregnancy 3 (10) 2 (8.7) >0.20 5 (9.4)
COPD 3 (10) 2 (8.7) >0.20 5 (9.4)
Cardiac insufficiencya 3 (10) 2 (8.7) >0.20 5 (9.4)
Neurological impairmentb 1 (3.3) 2 (8.7) >0.20 3 (5.7)
Haematological malignancy 2 (6.7) 1 (4.3) >0.20 3 (5.7)
Organ transplant 2 (6.7) 1 (4.3) >0.20 3 (5.7)
Neuromuscular disease 2 (6.7) 1 (4.3) >0.20 3 (5.7)
Prematurityb 1 (3.3) 1 (4.3) >0.20 2 (3.8)
HIV/AIDS 0 (0) 2 (8.7) 0.10 2 (3.8)
Renal insufficiency 0 (0) 1 (4.3) >0.20 1 (1.9)
Autoimmune disease 0 (0) 0 (0) – 0 (0)
None 7 (23.3) 4 (17.4) >0.20 11 (20.7)
BMI, body-mass index; COPD, chronic obstructive pulmonary disease.
aAll were adult patients.
bAll were paediatric patients.
378 Clinical Microbiology and Infection, Volume 18 Number 4, April 2012 CMI
ª2011 The Authors
Clinical Microbiology and Infection ª2011 European Society of Clinical Microbiology and Infectious Diseases, CMI, 18, 374–380
indices (Tables 1 and 2). Obesity and chronic respiratory dis-
eases were the most frequent risk factors; the prevalence of
obesity increased by 55.6% between the two surveyed peri-
ods [17]. Postpandemic ICU influenza A (H1N1) 2009 devel-
oped later; consistent with international observations,
influenza B virus conferred by 8.7% to the 2010–2011 winter
influenza cases admitted in our ICU (http://www.cdc.gov/mmwr/
preview/mmwrhtml/mm6006a4.htm?s_cid=mm6006a4_w).
A decrease of severe influenza infections with radiologi-
cal opacities was observed in the period September 2010–
January 2011. This was consistent with an increase in respi-
ratory syndromes such as exacerbation of asthma or
chronic obstructive pulmonary disease. Influenza A (H1N1)
2009 and RSV epidemics peaked simultaneously, affecting a
vulnerable population. Clinical presentation as severe bron-
chiolitis and co-infection with RSV in 42.8% of children
<2 years of age in the September 2010–January 2011 sea-
son is to our knowledge an observation reported for the
first time. Such coexistence could not be demonstrated in
adults. Prediction models of influenza dispersal had sug-
gested that co-infection with other viruses could trigger a
pandemic [18]. In contrast, circulation of human rhinovirus-
es was demonstrated to have a protective and delaying
effect [19]. It has been suggested that during infection and
shedding of rhinoviruses, a refractory period may develop
when superinfection of respiratory cells by other respira-
tory viruses is inhibited [20]. However, no data exist on
RSV and H1N1 co-infection. In a recent study co-infections
of influenza A and RSV ranged from 1% to 8% in two par-
ticipating centres in the 2009–2010 winter period and were
1% in the previous winter [21].
The fact that influenza A (H1N1) 2009 affected a more
vulnerable population with co-morbid conditions, would
anticipate a higher mortality in the period September 2010–
January 2011. This was not confirmed either in the total
cohort or in the subset of mechanically ventilated patients,
the mortality being arithmetically inferior in September
2010–January 2011. Several factors could have contributed
to this stability. First, more prompt diagnosis cannot be
excluded, although statistical difference could not be demon-
strated. Second, a better use of high-flow oxygenation (Opti-
flow) was achieved during the 2010–2011 period (data not
shown); a wiser recognition of patients at higher risk of fail-
ure may have contributed.
Other treatment-specific differences between the two sur-
veyed periods were the increased use of azithromycin and
the abandonment of corticosteroids as adjunctive treatment
for primary viral pneumonia. An immunomodulating effect of
macrolides has been demonstrated in the context of micro-
bial sepsis but no solid data exist in the context of influenza
A (H1N1) 2009 [22,23]. The reduction in the use of corti-
costeroids as adjunctive treatment of primary viral pneumo-
nia reflect our centre’s awareness that early use of
corticosteroids did not result in better outcomes and was
associated with superinfections [15].
Did we record an evolving face or an evolving way of
facing influenza A (H1N1) 2009 virus? Probably both are
true. The pandemics of 1918–1919 and 1889–1892 have
taught us that second and third waves were associated with
increased mortality compared with the initial wave [16,24],
which did not occur in our cohort despite the increased
severity scores upon admission of adults. Co-infections by
bacterial pathogens, with predominance of S. pneumoniae,
doubled in the second period, which is in line with histori-
cal data [24]. The prevalence of viral or bacterial co-infec-
tions was increased four-fold (OR 5.8, 95% CI 1.3–24.8).
Interestingly, 50% of all deaths in our cohort had bacterial
co-infections. Our improved ability to manage both compo-
nents with early antiviral and antibiotic treatment as well as
intensive care support provides perhaps an explanation why
mortality was not as high as in historical data [5,24].
Preventive strategies did not ameliorate during the two
surveyed periods, in line with other reports [5,25]. Vaccine
uptake was pretty much the same with only one patient vac-
cinated in 2010–2011 among ICU admitted patients; this was
a bi-pulmonary transplant recipient who ultimately died. Even
though inferior to that predicted by mathematical models,
paying a mortality toll for a preventable disease remains a big
challenge for 21st century medicine [26]. None of the preg-
nant women was vaccinated either; moreover they had a
remarkably long course before seeking antiviral treatment
(>5 days).
The strengths of our study could be summarized as fol-
lows: it originates from a single centre, with a homogeneous
treatment strategy, representative of a big population base in
Catalonia, Spain. The number of patients presented herein is
one of the largest in the literature deriving from single cen-
tres and the analysis of the paediatric cases adds significant
epidemiological data. The study has certain weaknesses. First,
the small number of patients does not permit the evaluation
of outcomes with significant statistical power. Second, the
inclusion of a single centre does not allow for extrapolations
to a more extended population.
In conclusion, during the first postpandemic year, primary
viral pneumonia still predominated among ICU admissions
for influenza, whereas cases of sever acute respiratory infec-
tion without chest X-ray opacities increased. Enhanced vacci-
nation practices among risk groups are warranted to prevent
ICU admission and death. Early access to antiviral treatment
should be strongly encouraged.
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